Photo from IASLC/X
Jul 31, 2024, 09:17
New Lung Cancer Considered episode, the use of ICIs in the treatment of molecular driven NSCLC
IASLC shared on X:
“In this Lung Cancer Considered episode, Narjust Florez and 2 esteemed oncology colleagues discuss an evolving hot topic: the use of immune checkpoint inhibitors in the treatment of patients with molecular driven NSCLC. With guests Erin Schenk and Biagio Ricciuti.”
Narjust Florez shared IASLC’s post, adding:
“Amazing discussion about use of Immuno-oncology in patients with Lung Cancer with driver mutations.
Highly recommend this episode, so much learning for these two great guests Drs. Erin Schenk and Biagio Ricciuti.”
Source: IASLC/X and Narjust Florez/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 17:57
Nov 14, 2024, 17:46
Nov 14, 2024, 17:46
Nov 14, 2024, 17:42
Nov 14, 2024, 17:14